Weekly Medical Affairs Briefing: Cosentyx

Week ending 23 August 2026

1. Clinical accuracy snapshot

AI answers generally captured several core label-aligned points: Cosentyx targets IL-17A; no renal or hepatic dose adjustment is generally recommended; known serious hypersensitivity is the principal contraindication; active clinically important infection warrants clinical evaluation and possible treatment interruption; and Cosentyx does not carry a boxed warning.

However, label accuracy is inconsistent in clinically consequential areas. The clearest disagreement concerns plaque psoriasis dosing:

• Most variants stated 300 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, followed by every-4-week maintenance.
• One variant stated loading at Weeks 0–3 only.
• Maintenance timing varied among “after Week 4,” “Week 5,” and Week 8.

This is a material content gap requiring correction in any AI-facing or standard-response source. The active-infection answers also vary between “do not start or continue,” “hold,” and “contact the prescriber,” without consistently distinguishing label language from clinical practice.

Monitoring responses frequently described TB testing as “required” and hepatitis screening or routine bloodwork as standard. These statements may reflect common clinical practice but should be separated from what the prescribing information explicitly requires. Responses also inconsistently included IBD, candidiasis, hypersensitivity, and pregnancy-related considerations. The 26 cross-response inconsistency flags overall—up from 24 last week—indicate persistent variability, not a PV signal by themselves.

2. Off-label and substitution handling

Off-label discussion remained limited (3 tagged mentions, versus 1 last week). Answers generally acknowledge that claims should be tied to the approved population, endpoint, comparator, and timeframe, but the boundary is not always explicit. For example, responses describe marketing claims such as “rapid skin clearance” and “durable response” without consistently directing users to the indication-specific label and source evidence.

Substitution questions generated 11 biosimilar/generic mentions. Answers appropriately state that biologics do not have traditional small-molecule generics and that substitution depends on jurisdiction, payer, pharmacy policy, and interchangeability status. However, several answers imply that secukinumab biosimilars are available without identifying an approved product or current jurisdiction-specific status. This could mislead patients about automatic pharmacy substitution. No compounded-product signal was reported.

3. Unmet information needs

Recurring needs suitable for Medical Information or HCP content include:

• A label-accurate dosing table by indication, age/weight group, formulation, loading regimen, and maintenance timing.
• Practical guidance on active infection, TB screening, vaccines, and ongoing monitoring, distinguishing label requirements from customary practice.
• A focused pregnancy/lactation FAQ, including infant exposure and live-vaccine guidance; answers varied substantially in specificity.
• Clear explanation of Cosentyx versus Taltz, Humira, Stelara, and Enbrel, using indication-specific comparative evidence rather than “stronger,” “best,” or “superior.”
• A current generic/biosimilar and pharmacy-substitution resource explaining that interchangeability and substitution are jurisdiction-specific.

4. Change over time

Inconsistency flags rose from 24 to 26 this week, remaining below the 28 seen on 26 July but indicating no sustained resolution. Off-label mentions increased from 1 to 3; biosimilar/generic mentions increased from 9 to 11, although both remain within the recent range. Infection-risk mentions increased from 78 to 87 and IBD flags from 32 to 40, reinforcing the need for consistent safety-context language. The rise may partly reflect increased response volume, but the dosing discrepancy is a distinct clinical-accuracy concern.

5. Recommended actions

1. Prioritize correction of the dosing standard response and test all indication/device variants; specifically resolve the 4-dose versus 5-dose and Week 4/5 versus Week 8 discrepancies.
2. Update PI-based FAQs for infection management, TB/hepatitis screening, monitoring, contraindications, pregnancy, and infant vaccines, clearly labeling “label” versus “clinical practice.”
3. Create a substitution FAQ reviewed by Regulatory/Legal/Medical Information, avoiding unsupported claims about current secukinumab biosimilar availability or automatic substitution.
4. Develop neutral comparative-language guidance for HCP and patient content, emphasizing indication-specific evidence and avoiding “stronger,” “best,” or “superior.”
5. Continue weekly monitoring of dosing and special-population questions; route safety-event implications separately through PV rather than treating content inconsistency as a safety signal.